PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Snap-8: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for Snap-8 across studied indications.

Back to Snap-8 overview

Research Summary

Snap-8 has zero peer-reviewed human RCTs and zero independent clinical studies. All cited efficacy data comes from cosmetic ingredient supplier studies that have not been published in medical literature or independently verified. The fundamental question — whether Snap-8 can penetrate skin deeply enough to reach neuromuscular junctions — remains unanswered. The molecular weight (~1,075 Da) exceeds the ~500 Da threshold typically needed for efficient skin penetration. A 2016 JDD peptide serum trial referenced acetyl octapeptide-3 in a multi-ingredient product but did not isolate Snap-8 effects. Snap-8 is classified as a cosmetic ingredient, not a drug, in all jurisdictions.

Evidence by Indication (2 indications)

Indication Tier Trials Summary
Wrinkle reduction Tier D 0 Zero peer-reviewed human RCTs; all data from cosmetic supplier studies
Expression line prevention Tier D 0 In vitro SNARE complex inhibition only; no in vivo human confirmation

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (2 sources)

  1. 1. SNAP-25 protein structure and SNARE complex assembly in neurotransmitter release Review

    Jahn R, Scheller RH (2006), Nature Reviews Molecular Cell Biology

  2. 2. Topical peptides as cosmeceuticals Review

    Gorouhi F, Maibach HI (2009), International Journal of Cosmetic Science